Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

Molecular imaging’s technological advances are impressive, but getting the business model right and investors on board has been hard for start ups in the field. FluoroPharma CEO Thijs Spoor believes his company, which has several cardiovascular imaging agents in clinical trials, is on the right track and ripe for partnerships.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.